Acid-degradable particles for protein-based vaccines: enhanced survival rate for tumor-challenged mice using ovalbumin model.

Acid-degradable protein-loaded polymer particles show promise for antigen-based vaccines due to their ability to activate cytotoxic T lymphocytes (CTLs) in vitro. Protein loadings and cytotoxic T lymphocyte activation efficiencies have now been enhanced through novel delivery vehicle designs. In particular, the use of a more hydrophilic acid-degradable cross-linker leads to increased water dispersibility and increased protein loading efficiency for the particles. A 2.5-fold increase in protein encapsulation allows the delivery of more protein antigen to antigen presenting cells (APCs) leading to a 20-fold rise in antigen presentation levels. The mechanism by which APCs internalize these particles was explored using the phagocytosis inhibitor, cytochalasin B. In addition, preliminary in vivo experiments were conducted to investigate the ability of the protein-loaded particles to provide immunity against tumors in mice, and an enhanced survival rate over the use of protein alone was observed, indicating that this vaccine delivery strategy has great practical potential.

[1]  Jean M. J. Fréchet,et al.  A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  T. Kissel,et al.  Synthesis of bioadhesive poly(acrylic acid) nano- and microparticles using an inverse emulsion polymerization method for the entrapment of hydrophilic drug candidates. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[3]  E. Engleman,et al.  Dendritic cells in cancer immunotherapy. , 2000, Annual review of immunology.

[4]  K. Schaumburg,et al.  Thioalkylated tetraethylene glycol: a new ligand for water soluble monolayer protected gold clusters. , 2002, Chemical communications.

[5]  S. Stolnik,et al.  COLLOIDAL STABILITY AND DRUG INCORPORATION ASPECTS OF MICELLAR-LIKE PLA-PEG NANOPARTICLES , 1999 .

[6]  B. Tirosh,et al.  MHC class I‐restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope , 1999, European journal of immunology.

[7]  D. Montefiori,et al.  Prospects for vaccine protection against HIV-1 infection and AIDS. , 2002, Annual review of immunology.

[8]  M. Merad,et al.  In vivo manipulation of dendritic cells to induce therapeutic immunity. , 2002, Blood.

[9]  I. Sjöholm,et al.  Immobilization of proteins in microspheres of biodegradable polyacryldextran. , 1980, Journal of pharmaceutical sciences.

[10]  K. Rock,et al.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. Finkelmann,et al.  Shapes of Micelles and Molecular Geometry Synthesis and Studies on the Phase Behaviour, Surface Tension and Rheology of Rigid Rod-Like Surfactants in Aqueous Solutions , 1988 .

[12]  M. Cotten,et al.  Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. , 1999, Human gene therapy.

[13]  R. Vabulas,et al.  Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells , 1998, European journal of immunology.

[14]  M. Bevan,et al.  Introduction of soluble protein into the class I pathway of antigen processing and presentation , 1988, Cell.

[15]  K. Mills,et al.  Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. , 1995, Vaccine.

[16]  S. Hwang,et al.  Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7. , 2000, Vaccine.

[17]  G. Goldstein.  HIV–1 Tat protein as a potential AIDS vaccine , 1996, Nature Medicine.

[18]  J. Swanson,et al.  The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation. , 1997, Vaccine.

[19]  N. Shastri,et al.  Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Rechsteiner,et al.  Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles , 1982, Cell.

[21]  I. M. Belyakov,et al.  Strategies for designing and optimizing new generation vaccines , 2001, Nature Reviews Immunology.

[22]  I. Sjöholm,et al.  Incorporation of macromolecules in microparticles: preparation and characteristics. , 1976, Biochemistry.

[23]  S. Blower,et al.  Live attenuated HIV vaccines: Predicting the tradeoff between efficacy and safety , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Y Li,et al.  PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[25]  R. Sakakibara,et al.  Liposome oligomannose‐coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes , 1998, FEBS letters.

[26]  P. Artursson,et al.  Microparticles as potentially orally active immunological adjuvants. , 1989, Vaccine.

[27]  N. Murthy,et al.  A novel strategy for encapsulation and release of proteins: hydrogels and microgels with acid-labile acetal cross-linkers. , 2002, Journal of the American Chemical Society.